Search clinical trials for: Advagraf®

Total 13863 results

University of British Columbia
Simon Fraser University; Astellas Pharma Canada, Inc.

Completed

Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients

Renal Transplant | Renal Disease

Canada
Assistance Publique - Hôpitaux de Paris

Completed

Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation (Conversion)

Immunosuppression After Liver Transplantation

France
Astellas Pharma Europe Ltd.

Completed

Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients (CHORUS)

Kidney Transplantation

Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, Serbia, Spain, Taiwan, Thailand, United Kingdom, Vietna...
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

Kidney Transplantation

United States, Canada
Chiesi Farmaceutici S.p.A.

Completed

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients (STEADY)

End Stage Renal Disease

Italy
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients

Organ or Tissue Transplant; Complications

France
Hannover Medical School

Terminated

Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation

Lung Transplantation

Germany
Astellas Pharma S.A.S.

Completed

A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®) (OPALE)

Renal Transplantation

France
Astellas Pharma Canada, Inc.

Completed

A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers

Healthy

Canada
Astellas Pharma Global Development, Inc.

Completed

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients (ASTOUND)

Kidney Transplantation

United States
Astellas Pharma Inc

Completed

A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients

Liver Transplantation

United States
Astellas Pharma Europe Ltd.

Completed

A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Czechia, France, Italy, Poland, United Kingdom
Technische Universität Dresden

Active, not recruiting

Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen (S&L)

Renal Insufficiency, Chronic | Renal Insufficiency | Renal Failure | Renal Disease

Germany
Astellas Pharma Europe Ltd.

Completed

Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Spain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
Astellas Pharma Europe Ltd.

Active, not recruiting

Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Liver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine Transplantation

Belgium, Czechia, France, Germany, Italy, Poland, United Kingdom
Yonsei University

Completed

Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients

Kidney Transplant Patients

Korea, Republic of
Linical Korea
National Cancer Center, Korea; Astellas Pharma Korea, Inc.

Completed

To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients (Assign)

Liver Transplantation
Astellas Pharma Inc

Completed

Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation (OPTIMIZE)

Kidney Transplantation

Taiwan, Korea, Republic of
Kim, Seoung-Hoon
Astellas Pharma Korea, Inc.; Linical Korea

Completed

To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients

Liver Transplantation
Sandoz

Withdrawn

Study to Compare Pharmacokinetics of Tacrolimus Prolonged-release (PR) Capsules and Advagraf® PR Capsules in Stable Kidney Transplant Patients. (TODAY)

Kidney Transplant

France, Germany
UMC Utrecht

Completed

Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients

Atopic Dermatitis

Netherlands
Rabin Medical Center
Astellas Pharma Inc; Teva Pharma

Unknown

Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus (Advagraf)

Medication Adherence

Israel
National Taiwan University Hospital
Astellas Pharma Taiwan, Inc.

Unknown

Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant

Adherence to Medication Regime

Taiwan
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients

Liver Transplantation

United States
Novartis Pharmaceuticals

Completed

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients (EVITA)

Renal Transplant

Spain
University of Saskatchewan
Astellas Pharma Canada, Inc.

Completed

Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk (ESTTEROD)

Cardiovascular Diseases | Kidney Transplantation | Immunosuppression

Canada
Sun Yat-sen University

Completed

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis

Nephritis, Lupus

China
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients (COSMOS)

Kidney Transplant

Korea, Republic of
University Hospital, Tours
Astellas Pharma Inc

Unknown

Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE) (ADEQUATEartère)

De Novo Transplant Disease

France
University Hospital, Tours
Astellas Pharma Inc

Unknown

Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE) (ADEQUATE)

De Novo Transplant Disease

France
Ajou University School of Medicine

Completed

Once-a-day Immunosuppression(CISECON_a_day) (CISECON)

Chronic Renal Disease

Korea, Republic of
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Completed

Comparison of Extended Release Tacrolimus (Advagraf) and Cyclosporine A Microemulsion on Renal Function in Healthy Volunteers

Healthy

Canada
Sun Yat-sen University

Completed

The Efficacy and Tolerance of Tacrolimus Sustained-release Capsules on Refractory Nephrotic Syndrome (RNS)

Nephrotic Syndrome

China
Universitätsklinikum Hamburg-Eppendorf

Completed

Study to Evaluate Pharmacokinetic and Bioavailability of Envarsus® vs. Advagraf® in Liver Transplant Recipients

Liver Transplantation

Germany
Foundation for Liver Research

Completed

Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus

Liver Disease

Netherlands
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

Graft Rejection | Kidney Failure

United States, Spain, Canada, Switzerland, Austria, Australia, New Zealand
University of North Carolina, Chapel Hill

Completed

Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients (TAC3A5)

Renal Transplant

United States
Hospital Universitari de Bellvitge
Institut d'Investigació Biomèdica de Bellvitge

Unknown

Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury (TACROVID)

COVID-19 | Lung Injury

Spain
Pfizer

Completed

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Renal Transplant | Graft Rejection | Kidney Transplant | Renal Allograft Recipients

United States, Australia, Germany, Italy, Spain, Brazil, Argentina
Linical Korea
Asan Medical Center

Completed

Evaluate the Efficacy and Safety of the ADVAGRAF® (STABLE)

Evidence of Liver Transplantation

Korea, Republic of
Astellas Pharma Europe Ltd.

Completed

A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant (ADDRESS)

Liver Transplant | Kidney Transplant

Italy, Spain, Belgium, Germany, Latvia, Canada, Korea, Republic of, Czechia, Austria, Finland, Belarus, Estonia, France, Hungary, Ireland, Netherlands, Poland, Portugal, Romania, Russian Federation, Slovakia, Sweden, Switzerland, United...
Seoul National University Hospital

Unknown

Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion

Liver Dysfunction

Korea, Republic of
Astellas Pharma Europe Ltd.

Terminated

To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks

Validation | Dried Blood Spot | Transplant Patients

France, United Kingdom
Astellas Pharma S.A.S.

Completed

A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year (COBALT)

Liver Transplantation

France
Technical University of Munich

Completed

PEL-1235_REN-0176-I (Pelicon) (Pelicon)

Immunosuppression After Kidney Transplantation

Germany
Medical University of Warsaw

Recruiting

Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patients After Liver Transplantation : Single Center Randomised Control Trial

Immunosuppression | Liver Transplant Rejection

Poland
Chang Gung Memorial Hospital
Astellas Pharma Taiwan, Inc.

Recruiting

A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant

Liver Transplantation

Taiwan
Astellas Pharma Europe Ltd.

Completed

A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients (MITRA)

Liver Transplantation | Kidney Transplantation

France, United Kingdom
Seoul National University Hospital

Completed

Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients

Kidney Transplantation | Pediatric Patients | Maintenance With Tacrolimus

Korea, Republic of
Astellas Pharma Inc

Completed

Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients

Kidney Transplantation

United States, Canada, Brazil

3

Subscribe